Effectiveness and Safety of Antiobesity Medications in Patients With Obesity and Inflammatory Bowel Disease

被引：3
|
作者：
Pham, Jonathan T. [1 ]
Ghusn, Wissam [2 ,3 ]
Acosta, Andres [2 ,3 ]
Loftus, Edward V. [2 ]
Johnson, Amanda M. [2 ]
机构：
[1] Mayo Clin, Coll Med & Sci, Dept Internal Med, Rochester, MN USA
[2] Mayo Clin, Coll Med & Sci, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA
[3] Mayo Clin, Coll Med & Sci, Precis Med Obes Program, Rochester, MN USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 06期
关键词：
inflammatory bowel disease; obesity; Crohn's disease; ulcerative colitis; antiobesity medications; CEREBROVASCULAR ACCIDENTS; RISK;
D O I：
10.14309/ajg.0000000000002490
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
INTRODUCTION: Limited data exist evaluating antiobesity medications (AOM) in patients with inflammatory bowel disease (IBD). METHODS: We performed a case-control study evaluating the effectiveness and safety of AOM in patients with IBD with obesity, matched to non-IBD controls. RESULTS: After 12 months, the case (n = 36) and control (n = 36) groups achieved similar percent total body weight loss of -6.9 +/- 8.3 and -8.1 +/- 7.0 (P = 0.30), respectively. Side effect profiles were similar between groups. Seven patients experienced an IBD flare, all managed medically. DISCUSSION: AOM use in patients with IBD demonstrated similar effectiveness and safety when compared with that observed in the non-IBD population.
引用
收藏
页码：1197 / 1200
页数：4
相关论文
共 50 条
  • [21] Obesity in Inflammatory Bowel Disease: A Marker of Less Severe Disease
    Avegail Flores
    Ezra Burstein
    Daisha J. Cipher
    Linda A. Feagins
    Digestive Diseases and Sciences, 2015, 60 : 2436 - 2445
  • [22] Obesity in Inflammatory Bowel Disease: A Marker of Less Severe Disease
    Flores, Avegail
    Burstein, Ezra
    Cipher, Daisha J.
    Feagins, Linda A.
    DIGESTIVE DISEASES AND SCIENCES, 2015, 60 (08) : 2436 - 2445
  • [23] Obesity Does Not Impact Perioperative or Postoperative Outcomes in Patients with Inflammatory Bowel Disease
    Guardado, Jesse
    Carchman, Evie
    Danicic, Ashley E.
    Salgado, Javier
    Watson, Andrew R.
    Celebrezze, James P.
    Medich, David S.
    Holder-Murray, Jennifer
    JOURNAL OF GASTROINTESTINAL SURGERY, 2016, 20 (04) : 725 - 733
  • [24] Obesity and inflammatory bowel disease: diagnostic and therapeutic implications
    Swanson, Sophia M.
    Harper, Jason
    Zisman, Timothy L.
    CURRENT OPINION IN GASTROENTEROLOGY, 2018, 34 (02) : 112 - 119
  • [25] Effectiveness and Safety of the Switch from Remicade® to CT-P13 in Patients with Inflammatory Bowel Disease
    Chaparro, M.
    Garre, A.
    Guerra Veloz, M. F.
    Vazquez Moron, J. M.
    De Castro, M. L.
    Leo, E.
    Rodriguez, E.
    Carbajo, A. Y.
    Riestra, S.
    Jimenez, I.
    Calvet, X.
    Bujanda, L.
    Rivero, M.
    Gomollon, F.
    Benitez, J. M.
    Bermejo, F.
    Alcaide, N.
    Gutierrez, A.
    Manosa, M.
    Iborra, M.
    Lorente, R.
    Rojas-Feria, M.
    Barreiro-de Acosta, M.
    Kolle, L.
    Van Domselaar, M.
    Amo, V.
    Arguelles, F.
    Ramirez, E.
    Morell, A.
    Bernardo, D.
    Gisbert, J. P.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 (11) : 1380 - 1386
  • [26] Is safety infliximb during pregnancy in patients with inflammatory bowel disease?
    Arguelles Arias, Federico
    Castro Laria, Luisa
    Barreiro-de Acosta, Manuel
    Garcia Sanchez, M. Valle
    Guerrero Jimenez, Pedro
    Gomez Garcia, M. Rosa
    Cordero Ruiz, Patricia
    Iglesias Flores, Eva
    Gomez Camacho, Federico
    Munoz, Enrique J. Dominguez
    Herrerias Gutierrez, Juan Manuel
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2012, 104 (02) : 59 - 64
  • [27] Efficacy and safety of infliximab and adalimumab in inflammatory bowel disease patients
    Kamal, Mahmoud E.
    Werida, Rehab H.
    Radwan, Mahasen A.
    Askar, Safaa R.
    Omran, Gamal A.
    El-Mohamdy, Marwa A.
    Hagag, Radwa S.
    INFLAMMOPHARMACOLOGY, 2024, 32 (05) : 3259 - 3269
  • [28] Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease
    Venkata R. Satyam
    Pei-Hsuan Li
    Jason Reich
    Taha Qazi
    Ansu Noronha
    Sharmeel K. Wasan
    Francis A. Farraye
    Digestive Diseases and Sciences, 2020, 65 : 2986 - 2991
  • [29] Complementary and alternative medications in the management of inflammatory bowel disease
    Picardo, Sherman
    Altuwaijri, Mansour
    Devlin, Shane M.
    Seow, Cynthia H.
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2020, 13
  • [30] Effectiveness and safety of a GLP-1 agonist in obese patients with inflammatory bowel disease
    Belinchon, Clara Ramos
    Martinez-Lozano, Helena
    Moreno, Clara Serrano
    Castillo, Diego Hernandez
    Chicharro, Pablo Lois
    Ocampo, Pablo Ferreira
    Marin-Jimenez, Ignacio
    Lesmes, Irene Breton
    Menchen, Luis
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2024, 116 (09) : 478 - 483
12345